1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: 
Treatments and outcomes stratified by fistula complexity
All Subjects n = 25 Single-Hole Fistulas n = 9 Multi-Hole Fistulas n = 16 P Value
Treatments 
    Mean age of first treatment ± SD 4.9 ± 6.5 y 9.4 ± 7.3 y 2.3 ± 4.5 y .021
    Median age (range) of first treatment 1.7 y (1 day to 25 y) 7 y (3–25 y) 0.62 y (1 day to 16 y) 
    Median treatment procedures (range) 2 (1–5) 2 (1–2) 3 (1–5) .003
    Endovascular treatments only 60% 67% 56% .69
    Any periprocedural complication 60% 22% 81% .009
    Any symptomatic complication 32% 22% 38% .66
Outcomes at last follow-up 
    Mean follow-up duration ± SD 3.3 ± 3.3 y 4.3 ± 4.1 y 2.7 ± 2.6 y .33
    Median (range) follow-up duration 2 y (1 day to 13 y) 4 y (2 days to 13 y) 1.8 y (1 day to 7 y) 
    Occlusion of all targeted arteriovenous shunts 72% 78% 69% 1.0
    Elimination of all arteriovenous shunting 60% 78% 38% .097
    White matter calcifications 25% 0% 35% .26
    Normal neurologic examination 48% 100% 19% .0001
    Median last mRS (range) 1 (0–6) 0 (0) 2 (0–6) <.0001
    Good outcome (last mRS 0–2) 72% 100% 56% .027